On April 5, 2024 Tempus, a leader in artificial intelligence and precision medicine, reported 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which convenes from April 5-10, in San Diego, California (Press release, Tempus, APR 5, 2024, View Source [SID1234641825]). Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting 18 abstracts at AACR (Free AACR Whitepaper) this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators," said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. "Our research showcases the power of combining our molecular profiling offerings with our multimodal database to better understand cancer biology, treatment response, and patient outcomes."

Research highlights include:

Poster Presentation: A circulating tumor fraction DNA biomarker response stratified by ESR1 mutation status correlates with overall survival in patients with HR+ HER2- metastatic breast cancer
Session Date & Time: Monday, April 8, 2024; 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 41
Overview: Tempus xM used for treatment response monitoring (TRM) is an algorithm that quantifies changes in circulating DNA tumor fraction (TF) and can be simultaneously used to detect the emergence of ESR1 mutation (ESR1m) variants. In a heterogeneous real-world cohort of ER+ HER2- metastatic breast cancer patients, we showed that the combined effect of molecular response and ESR1 mutation status, a mutation associated with resistance to aromatase inhibitors (AIs), was associated with real-world overall survival outcomes. These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.
Abstract: Leveraging a comprehensive genomic data library for detecting clonal hematopoiesis in liquid biopsy
Session Date & Time: Monday, April 8, 2024; 9:00 a.m. – 12:30 p.m. PT
Location: Poster Section 37
Overview: To more efficiently filter out clonal hematopoiesis (CH) variants from tumor-derived variants, the team trained a random forest classifier on advanced, pan-solid tumor cancer samples sequenced using liquid biopsy and solid-tumor NGS with matched buffy coat assays (n=660). On a held-out validation set of samples (n=661), the classifier could reliably distinguish between CH and other tumor-derived variants with high accuracy, sensitivity, and specificity using only liquid biopsy data for predictions, providing an operationally simpler alternative to combined liquid and solid-based methodologies.
Poster Presentation: Association of a ctDNA biomarker of treatment response with clinical outcomes in a real-world pan-cancer cohort treated with tyrosine kinase inhibitors
Session Date & Time: Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PT
Location: Poster Section 44
Overview: By analyzing changes in circulating DNA tumor fraction (ctDNA TF) in a real-world pan-cancer cohort of patients treated with Tyrosine kinase inhibitors (TKIs), the research team found that patients classified as molecular responders (defined as ≥ 50% in ctDNA tumor fraction) had significantly improved real-world overall survival and progression-free survival compared to molecular non-responders. Based on these findings, xM used for TRM may be used to optimize treatment decision making for patients treated with TKIs, sparing patients who do not respond to TKIs from ineffective therapy.
To learn more, visit www.tempus.com/events/aacr-annual-meeting-2024.